A Breakthrough in Metabolic & Neuro-Immune Medicine
At utR Biotech, we are developing a first-in-class therapy built on two patent-protected scientific breakthroughs:
- a novel cell-culture technology that restores normal metabolic signaling and dramatically improves cell performance, and
- a therapeutic co-formulation of insulin with our protein, designed to restore the natural hormonal coordination lost in diabetes and related disorders.
A Lost Biological Signal—Now Recovered
Modern insulin therapies replace only half of a natural hormonal pair. The absence of a protein leads to metabolic stress, chronic inflammation, accelerated complications, and impaired cellular function. Our patented platform restores this missing coordination. Early data demonstrate:
- 7-fold greater mass-efficiency compared to insulin alone
- Improved metabolic stability and reduced cellular stress
- Potential to slow or prevent diabetic complications affecting such as neuropathy, retinopathy, MAFLD, cardiovascular disease, autoimmune disorders, certain cancers, and diabetic skin.
- A novel dual-pathway neuroprotective mechanism with potential relevance for Alzheimer’s disease
Two Complementary Patents, One Unified Platform
1. Advanced Cell-Culture System
Our first patent introduces a physiologically balanced cell-culture medium that pairs insulin with the protein to eliminate the artificial “diabetic state” found in all conventional media. This significantly improves therapeutic cell expansion, antibody production, and metabolic performance.
2. Therapeutic Co-Formulation
Our second patent covers a pharmaceutical formulation that delivers insulin and the protein together, restoring the natural hormonal ratio the human body depends on. This approach is designed for rapid clinical translation, including eligibility for the U.S. 505(b)(2) pathway.
A Platform With Global Potential
These inventions unlock a coordinated metabolic network affecting inflammation, fibrosis, vascular health, and neuro-immune function. The result is a pipeline with applications across:
- Diabetes & metabolic disease
- Neurodegenerative conditions
- Regenerative medicine & cell therapy manufacturing
- Biologic drug production
Why Invest Now
- Strong IP position across both U.S. and Canadian markets
- Clear regulatory path with established safety profiles for core components
- Large, underserved markets seeking safer and more physiologic therapies
- Multiple revenue verticals—therapeutics, biologics manufacturing, diagnostics, and licensing
The Opportunity
utR Biotech is entering strategic partnerships and accepting engagement from qualified U.S. and Canadian investors. This communication is not an offer of securities; any participation will occur through proper regulated channels and compliant offering documents.
Call to Action
Join us in advancing the next generation of metabolic and neuro-immune medicine.
Contact our leadership team to explore partnership, licensing, or future investment opportunities.
Standard Investor Disclaimer
This webpage and its contents are provided for informational purposes only and do not constitute an offer to sell or a solicitation of an offer to buy any securities of utR Biotech or its affiliates. Any offering of securities will be made only in compliance with applicable securities laws, through formal offering documents provided to qualified or accredited investors in the United States and Canada. Forward-looking statements involve risks, uncertainties, and assumptions; actual results may differ materially. utR Biotech makes no commitment to update or revise any forward-looking statements except as required by law. No investment decision should be made based on the information presented here. Prospective investors should seek independent financial, legal, and tax advice.